Skip to content
stoqly

Roivant Sciences

ROIV Nasdaq Biotechnology Financials FY2020–FY2025

Roivant Sciences' revenue fell 71.6% to $8 million in fiscal 2025. Its operating margin was −6,235.7%, down from −3,453.3% a year earlier. Free cash flow was −$759 million. The diluted share count fell 4.3%.

Last close · Oct 23, 2026

$36.49

2.6%
Value it Compare
Revenue Total sales reported in the income statement.
$8.3M
71.5% vs prior year
Operating margin Operating income as a share of revenue.
−6,235.7%
2,782.4 pts
Net income Profit after all expenses, interest and tax.
−$300M
Free cash flow Cash from operations minus capital spending.
−$759M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−62.6%
Market cap Last close times the latest diluted share count, so it is approximate.
$26.3B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—

About these figures. Roivant had no borrowings after it sold Dermavant in 2024, so its debt counts as zero from fiscal 2024 (Roivant's fiscal 2025 is the year to March 2026), and with no interest expense in fiscal 2025, interest coverage is blank for that year.

What Roivant Sciences does

No business description yet.

Legal name
ROIVANT SCIENCES LTD.
Fiscal year ends
March 31, 2026
Latest annual report
—
Accession · CIK
0001635088-26-000061
0001635088

Revenue and margins

Roivant Sciences had $8.3M of revenue in fiscal 2025, down 71.6% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$759M in fiscal 2025, −9,183.5% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Roivant Sciences returned $0.0M to shareholders in fiscal 2025. The diluted share count fell 4.4%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Roivant Sciences yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of $4.3B and divides by 693.9M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Balance sheet

Cash, debt and the ratios that show how comfortably Roivant Sciences can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $2.1B$1.7B$6.5B$4.9B$4.3B
Debt incl. finance leases $210M$381M$431M$0.0M$0.0M
Net debt / EBITDA ——−1.3x——
Debt / equity 0.1x0.3x0.1x0.0x0.0x
Interest coverage −192.0x−32.4x129.3x−168.3x—
Current ratio 11.6x6.6x25.2x33.5x18.4x
Quick ratio 11.6x6.6x25.1x33.5x18.4x
Total assets $2.6B$2.4B$7.2B$5.4B$5.7B
Total liabilities $524M$782M$774M$250M$416M
Shareholders' equity $1.7B$1.2B$6.0B$4.7B$4.5B
Net debt (− = net cash) −$1.9B−$1.3B−$6.1B−$4.9B−$4.3B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$58.9M

4 insiders

Of sales under plans

38%

$22.4M

DateInsiderTradeSharesPriceValueFiling
Oct 20, 2026 Eric VenkerPresident & Immunovant CEO Sold plan 200,000 $35.11 $7.0M Form 4
Sep 15, 2026 Meghan FitzgeraldDirector Sold plan 5,112 $39.74 $0.2M Form 4
Sep 15, 2026 Melissa B EpperlyDirector Sold plan 4,938 $39.74 $0.2M Form 4
Sep 8, 2026 Meghan FitzgeraldDirector Sold plan 20,000 $39.90 $0.8M Form 4
Aug 28, 2026 Eric VenkerPresident & Immunovant CEO Sold plan 200,000 $35.77 $7.2M Form 4
Aug 21, 2026 Mayukh SukhatmePresident & CIO, Director Sold 144,756 $36.48 $5.3M Form 4
Aug 20, 2026 Mayukh SukhatmePresident & CIO, Director Sold 17,519 $37.30 $0.7M Form 4
Aug 19, 2026 Mayukh SukhatmePresident & CIO, Director Sold 172,899 $37.17 $6.4M Form 4
Aug 18, 2026 Mayukh SukhatmePresident & CIO, Director Sold 136,942 $36.73 $5.0M Form 4
Aug 17, 2026 Mayukh SukhatmePresident & CIO, Director Sold 284,707 $36.25 $10.3M Form 4
Aug 14, 2026 Mayukh SukhatmePresident & CIO, Director Sold 243,177 $36.23 $8.8M Form 4
Jul 27, 2026 Eric VenkerPresident & Immunovant CEO Sold plan 200,000 $34.95 $7.0M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✕ ✕
Cash from operations is positive ✕ ✕ ✕
Return on assets rose ✓ ✕ ✕
Cash from operations exceeds net income ✕ ✕ ✕
Debt fell relative to assets ✓ ✓ ✕
Current ratio rose ✓ ✓ ✕
Share count didn't rise ✕ ✓ ✓
Gross margin rose — — —
Revenue rose relative to assets ✓ ✕ ✕
F-score 5 / 83 / 81 / 8
Accruals ratio 106.4%10.6%8.1%
Altman Z'' 19.0626.4918.07

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Roivant Sciences ROIV $26.3B −71.6% −6,235.7% −9,183.5% −62.6% — 1
Cytokinetics CYTK — 376.6% −695.4% −607.5% — — — Compare →
Ligand Pharmaceuticals LGND $6.6B 60.4% 15.3% 18.2% 4.9% 32.3x 5 Compare →
Krystal Biotech KRYS $9.6B 33.9% 41.5% 48.6% 43.6% 39.0x 5 Compare →
ADMA Biologics ADMA $2.5B 19.6% 37.5% 5.5% 39.5% 15.3x 5 Compare →

6 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue $23.8M $55.3M $31.5M $32.7M $29.1M $8.3M
Research and development $237M $483M $454M $440M $550M $682M
Operating income −$1.1B −$1.4B −$907M $4.5B −$1.0B −$515M
Interest expense $2.8M $7.0M $28.0M $34.8M $6.0M $0.0M
Pretax income −$899M −$924M −$885M $4.6B −$682M −$265M
Income tax $1.7M $0.4M $4.1M $21.5M $48.2M $133M
Net income −$809M −$845M −$1.0B $4.3B −$172M −$300M
Diluted EPS −$1.28 −$1.26 −$1.42 $5.23 −$0.24 −$0.54
Diluted shares 0.63B 0.67B 0.71B 0.83B 0.73B 0.69B
Cash flow
Cash from operations −$552M −$678M −$843M −$765M −$840M −$750M
Capital expenditure $5.8M $17.4M $12.7M $1.4M $4.6M $8.2M
Free cash flow −$558M −$695M −$856M −$767M −$844M −$759M
Depreciation and amortization — $5.9M $18.9M $22.0M $14.1M $3.3M
Stock-based compensation $85.0M $565M $218M $200M $289M $346M
Acquisitions $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $0.0M $0.0M $0.0M $0.0M $1.3B $0.0M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $0.0M $0.0M $0.0M $1.3B $0.0M
Balance sheet
Cash and short-term investments $2.1B $2.1B $1.7B $6.5B $4.9B $4.3B
Total debt $170M $210M $376M $431M $0.0M $0.0M
Finance lease liabilities $0.0M $0.0M $5.7M $0.0M $0.0M $0.0M
Current assets $2.2B $2.1B $1.8B $6.7B $5.0B $5.2B
Current liabilities $219M $184M $272M $267M $149M $281M
Inventory $0.0M $0.0M $2.8M $35.3M $0.0M $0.0M
Property and equipment, net $14.7M $25.9M $39.1M $15.3M $12.1M $12.0M
Total assets $2.6B $2.6B $2.4B $7.2B $5.4B $5.7B
Total liabilities $528M $524M $782M $774M $250M $416M
Shareholders' equity $1.8B $1.7B $1.2B $6.0B $4.7B $4.5B
Margins
Operating margin −4,500.5% −2,444.8% −2,875.9% 13,746.9% −3,453.3% −6,235.7%
EBITDA margin — −2,434.1% −2,816.1% 13,814.3% −3,404.9% −6,195.2%
Net margin −3,400.9% −1,528.9% −3,200.2% 13,294.2% −592.0% −3,629.2%
FCF margin −2,344.8% −1,257.4% −2,715.1% −2,343.6% −2,905.2% −9,183.5%
Returns
Return on capital — — −286.2% — — −62.6%
Return on capital employed — −56.7% −40.1% 99.1% −16.4% −9.6%
Return on equity — −48.9% −71.7% 122.1% −3.2% −6.5%
Return on assets — −32.7% −40.6% 90.5% −2.7% −5.4%
Growth
Revenue growth — 132.3% −43.0% 3.8% −11.2% −71.6%
Net income growth — — — — −104.0% —
EPS growth — — — — −104.6% —
Share count change — 6.3% 6.4% 16.6% −12.7% −4.4%
Financial health
Net debt / EBITDA — — — −1.3x — —
Debt / equity 0.1x 0.1x 0.3x 0.1x 0.0x 0.0x
Interest coverage −381.2x −192.0x −32.4x 129.3x −168.3x —
Current ratio 10.0x 11.6x 6.6x 25.2x 33.5x 18.4x
Quick ratio 10.0x 11.6x 6.6x 25.1x 33.5x 18.4x
Capital allocation
Capex / revenue 24.4% 31.5% 40.3% 4.2% 15.8% 99.4%
Stock comp / revenue 357.0% 1,021.9% 690.7% 610.2% 994.8% 4,190.9%
Quality scores
Piotroski F-score — — 1.0 5.0 3.0 1.0
Altman Z'' 3.9 2.1 −1.4 19.1 26.5 18.1
Accruals ratio — −6.5% −6.7% 106.4% 10.6% 8.1%

Source: SEC EDGAR XBRL filings (CIK 0001635088). Data updated October 11, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open